EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line ARPI Therapy

Takeshi Tsutsumi, Shogo Yamazaki, Takuya Matsuda, Takuya Tsujino iD, Taizo Uchimoto, Takafumi Yanagisawa iD, Keiichiro Mori, Wataru Fukuokaya iD, Fumihiko Urabe iD, Masanobu Saruta, Atsuhiko Yoshizawa, Shingo Toyoda und 16 weitere

The Prostate · 2026

DOI: 10.1002/pros.70157 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2026. Verfasst von Takeshi Tsutsumi und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki City, Osaka, Japan. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms, Androgen Receptor Antagonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science: JSPS, Osaka Medical and Pharmaceutical University, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Radiographic progression (RP) without prostate‐specific antigen (PSA) elevation has emerged as a clinically important pattern in the androgen receptor pathway inhibitors (ARPI) era, but its prevalence and prognostic significance in real‐world metastatic hormone‐sensitive prostate cancer (mHSPC) cohorts remain unclear.

Objective

To assess the prevalence and prognostic implications of RP alone progression in mHSPC patients treated with first‐line ARPIs.

Methods

We retrospectively analyzed 518 mHSPC patients treated with abiraterone acetate plus prednisolone, enzalutamide, or apalutamide. PSA progression was defined using PCWG3 criteria. Patients were categorized into PSA progression or RP alone progression groups, and clinical outcomes were compared.

Results

Among 169 patients who developed castration‐resistant prostate cancer (CRPC), 34 (20.1%) experienced RP alone. RP alone patients had significantly worse overall survival compared to those with PSA progression (median 21 vs. 39 months, p = 0.007), despite exhibiting deeper biochemical responses—PSA nadir (0.055 vs. 0.86 ng/mL, p < 0.001) and a higher rate of PSA nadir < 0.2 ng/mL (61.8% vs. 27.4%, p < 0.001). The baseline characteristic differing between groups was CHAARTED volume classification; high volume disease was markedly more common in RP alone patients (94.1% vs. 77.8%). In univariate and multivariate analyses of the overall cohort, CHAARTED high volume disease was identified as an independent risk factor for RP alone (HR 10.3, 95% CI 1.20–89.3; p = 0.034).

Conclusion

RP alone progression occurred in approximately one‐fifth of patients and was associated with significantly poorer survival despite excellent PSA responses, underscoring the limitation of PSA‐based monitoring and supporting routine imaging for early detection of PSA‐incongruent disease progression in mHSPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsAndrogen Receptor AntagonistsHumansMaleDisease ProgressionRetrospective StudiesPrognosisAgedMiddle AgedAged, 80 and overNitrilesRadiography

Stichwörter der Autor:innen

ARPIprostate cancerradiographic progression

Substanzen

Prostate-Specific AntigenAndrogen Receptor AntagonistsNitriles

Autor:innen und Institutionen

  • Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki City, Osaka, Japan.
  • Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
  • Department of Urology, Fujita-Health University School of Medicine, Toyoake City, Aichi, Japan.
  • Department of Urology, Kindai University Faculty of Medicine, Sayama City, Osaka, Japan.
  • Department of Urology, Kawasaki Medical School, Okayama, Japan.
  • Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.

ORCID-Profile: Takuya Tsujino, Takafumi Yanagisawa, Wataru Fukuokaya, Fumihiko Urabe, Ryoichi Maenosono, Teruo Inamoto, Takahiro Kimura, Kazutoshi Fujita

Förderung

  • Japan Society for the Promotion of Science: JSPS
  • Osaka Medical and Pharmaceutical University
  • Japan Society for the Promotion of Science

Zitieren

APA

Tsutsumi, T., Yamazaki, S., Matsuda, T., Tsujino, T., Uchimoto, T., Yanagisawa, T., Mori, K., Fukuokaya, W., Fumihiko Urabe, Saruta, M., Yoshizawa, A., Toyoda, S., Fujimoto, S., Nishio, K., Sakamoto, M., Fukushima, T., Nakamura, K., Nishimura, K., Nakamori, K., …, & Azuma, H. (2026). The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line ARPI Therapy. The Prostate. https://doi.org/10.1002/pros.70157

Vancouver

Tsutsumi T, Yamazaki S, Matsuda T, Tsujino T, Uchimoto T, Yanagisawa T, et al. The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line ARPI Therapy. The Prostate. 2026. doi:10.1002/pros.70157

BibTeX
@article{Tsutsumi2026,
  author = {Tsutsumi, Takeshi and Yamazaki, Shogo and Matsuda, Takuya and Tsujino, Takuya and Uchimoto, Taizo and Yanagisawa, Takafumi and Mori, Keiichiro and Fukuokaya, Wataru and Fumihiko Urabe and Saruta, Masanobu and Yoshizawa, Atsuhiko and Toyoda, Shingo and Fujimoto, Saizo and Nishio, Kyosuke and Sakamoto, Moritoshi and Fukushima, Tatsuo and Nakamura, Ko and Nishimura, Kazuki and Nakamori, Keita and Matsunaga, Tomohisa and Yoshikawa, Yuki and Maenosono, Ryoichi and Takahara, Kiyoshi and Inamoto, Teruo and Kimura, Takahiro and Fujita, Kazutoshi and Komura, Kazumasa and Azuma, Haruhito},
  title = {The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line ARPI Therapy},
  journal = {The Prostate},
  year = {2026},
  doi = {10.1002/pros.70157}
}
Kostenlos starten →